查看购物车
  • Traditional Chinese
  • Japanese
  • Korean
近视管理市场（2025）
市场调查报告书
商品编码
1907771

近视管理市场（2025）

2025 Myopia Management Survey Report
出版日期: | 出版商: Market Scope, LLC | 英文 | 商品交期: 最快1-2个工作天内

价格
简介目录

Market Scope 的 "近视管理市场（2025）" 报告对美国儿童近视管理的现状进行了全面的提供者层面分析。报告考察了患者群体、治疗组合、经济状况、未满足的需求以及随着新型疗法进入市场可能出现的临床行为变化。

这项调查于 2025 年 8 月至 9 月进行，收集了 150 位美国验光师和眼科医生的见解，其中包括积极治疗近视的普通眼科医生和儿科眼科医生。受访者选自 Market Scope 的自註册医疗服务提供者社区，代表了在近视管理方面拥有直接经验的真实决策者。

本报告透过分析受访者层面的匿名调查数据，并排除市场整体估算，提供结构化的总结分析，清楚地阐述了医疗服务提供者的思考、处方、定价和规划。

目录：

"近视管理市场（2025）报告" 详细分析了医疗服务提供者接诊的患者数量、治疗方法以及采用或不采用特定治疗方法的原因。重点领域包括：

  • 医疗服务提供者状况与病患群体：儿科病患群体、近视盛行率（5-17 岁）以及参与积极近视矫正计画的病患比例。
  • 治疗方案采纳与临床策略：角膜塑形术、近视控制软性隐形眼镜、眼镜和低剂量阿托品在真实世界中的临床应用，包括一线治疗和联合治疗的趋势。
  • 角膜塑形术的应用与经济效益：处方镜片及品牌、每位患者的年用量、定价及捆绑策略、患者平均自付费用、满意度以及推广应用的障碍。
  • 低剂量阿托品处方：患者数量和处方量、厂商定价和患者自付费用、依从性和推广应用的障碍，以及FDA批准的无防腐剂配方上市后的预期变化。
  • 近视控制​​软式隐形眼镜：按品牌划分的使用情况、治疗持续时间、追踪频率、依从性挑战以及对疗效的认知。
  • 疗效、依从性和障碍：医疗服务提供者评估的儿童和成人近视治疗疗效、依从性挑战和推广障碍。
  • 在研疗法和市场发展：新兴疗法（包括阿托品释放镜片和重复低强度红光疗法 (RLRL)）的预期影响、定价和使用时间长度。
  • 技术与工作流程创新：对先进角膜塑形镜验配软体的信心以及可能推动医疗服务提供者采用该软体的因素。

研究方法：

Market Scope 于 2025 年 8 月至 9 月在美国开展了近视管理市场 (2025) 研究，旨在评估当前儿童近视管理实践的现状和新兴市场趋势。

在 Market-Scope.com 网站上自行註册的眼科医生和验光师（包括普通眼科医生和儿科眼科医生）均受邀参与本次调查。我们于 2025 年 9 月 5 日发送了电子邮件邀请，并于 2025 年 9 月 26 日发送了最终提醒。

本次调查共收到 150 份完整且唯一的回覆。所有结果均以匿名化后的医生报告数据的总结分析形式呈现，并根据每个问题的受访者人数进行计算，因为不同类型医生和执业领域的适用性有所不同。

我们未尝试对受访者群体以外的情况进行推论。问卷由 Market Scope 与赞助公司合作制定，所有资料均按照 Market Scope 的资料安全标准进行安全储存和管理。

简介目录

Market Scope's "2025 Myopia Management Survey Report" delivers a comprehensive, provider-level view of how pediatric myopia is being managed in the United States today-examining patient volumes, treatment mix, economics, unmet needs, and how clinical behavior is likely to shift as new therapies reach the market.

Conducted in August and September 2025, the survey captures insights from 150 US-based optometrists and ophthalmologists, including comprehensive and pediatric specialists actively treating myopia. Respondents were drawn from Market Scope's self-registered provider community and reflect real-world clinical decision-makers with direct experience in myopia control.

The report provides a structured summary analysis of de-identified survey data, calculated at the respondent level and presented without market extrapolation to clearly show how providers are thinking, prescribing, pricing, and planning.

Contents:

The "2025 Myopia Management Survey Report" delivers granular insight into how many patients providers are seeing, how they are treated, and why certain therapies are-or are not-used. Key areas of coverage include:

  • Provider Landscape & Patient Volumes: Pediatric patient loads, myopia prevalence (ages 5-17), and the share of patients enrolled in active myopia control programs.
  • Treatment Adoption & Clinical Strategy: Real-world use of ortho-k, myopia control soft contact lenses, spectacles, and low-dose atropine, including first-line and combination therapy preferences.
  • Ortho-K Utilization & Economics: Lenses and brands prescribed, annual volumes per patient, pricing and bundling strategies, average patient costs, satisfaction, and adoption barriers.
  • Low-Dose Atropine Prescribing: Patient and bottle volumes, manufacturer and patient pricing, compliance and adoption barriers, and expected shifts with FDA-approved, preservative-free options.
  • Myopia Control Soft Contact Lenses: Brand usage, treatment duration, follow-up cadence, compliance challenges, and perceived effectiveness.
  • Effectiveness, Compliance & Barriers: Provider-rated effectiveness by modality, compliance challenges, and pediatric and adult adoption barriers across treatments.
  • Pipeline Therapies & Market Evolution: Expected impact, pricing, and duration of use for emerging options, including atropine-eluting lenses and repeated low-level red-light therapy (RLRL).
  • Technology & Workflow Innovation: Willingness to trust advanced ortho-k fitting software and the factors most likely to drive provider adoption.

Methodology:

Market Scope conducted the 2025 Myopia Management Survey in the United States during August and September 2025 to assess real-world pediatric myopia management practices and emerging market trends.

Ophthalmologists and optometrists-including comprehensive and pediatric specialists-who self-registered on Market-Scope.com were invited to participate. Email invitations were distributed on September 5, 2025, with a final reminder sent on September 26, 2025.

The survey yielded 150 complete, unique responses. All results are presented as a summary analysis of de-identified, provider-reported data and are calculated based on the number of respondents for each question, as applicability varied by provider type and treatment mix.

No extrapolation beyond the respondent base was performed. Survey questions were developed by Market Scope in collaboration with sponsoring companies, and all data are securely stored and maintained in accordance with Market Scope's data security standards.